Search

Displaying results 2691 - 2700 of 10000 in total
  1. Drug

    Anthoxanthum odoratum pollen

    go.drugbank.com/drugs/DB10404
    Approved

    Anthoxanthum odoratum pollen is the pollen of the Anthoxanthum odoratum plant. Anthoxanthum odoratum pollen is mainly used in allergenic testing.

    Mixtures: Mixture of Standardized and Non-Standardized Coastal Grasses, Mixture of Twenty-Two Standardized and Non-Standardized Grasses
  2. Drug

    Aureobasidium pullulans var. pullutans

    go.drugbank.com/drugs/DB10427
    Approved

    Aureobasidium pullulans var. pullutans is a fungus which can provoke allergic reactions. Aureobasidium pullulans var. pullutans extract is used in allergenic testing.

    Mixtures: New Stock Fungi Mix, New Stock Fungi MixCategories: Non-Standardized Fungal Allergenic Extract
  3. Drug

    Benmoxin

    go.drugbank.com/drugs/DB09246
    ApprovedWithdrawn

    However, this agent is no longer marketed.

  4. Drug

    rCFP-10

    go.drugbank.com/drugs/DB21907
    Approved

    rCFP-10 is a recombinant culture filtrate protein of Mycobacterium tuberculosis used as an ingredient in the diagnostic agent SIILTIBCY along with rdESAT-6.

  5. Drug

    Rimonabant

    go.drugbank.com/drugs/DB06155
    ApprovedWithdrawn

    This decision was made after a U.S. advisory panel recommended the medicine not be approved because it may increase suicidal thinking and depression. … Rimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite.

  6. Drug

    Imiglucerase

    go.drugbank.com/drugs/DB00053
    ApprovedInvestigational

    Alglucerase is prepared by modification of the oligosaccharide chains of human Beta-glucocerebrosidase. … The modification alters the sugar residues at the non-reducing ends of the oligosaccharide chains of the glycoprotein so that they are predominantly terminated with mannose residues.

  7. Drug

    Ximelagatran

    go.drugbank.com/drugs/DB04898
    ApprovedWithdrawn

    Ximelagatran is an anticoagulant intended to become a replacement for warfarin by overcoming the dietary restrictions, drug interaction, and monitoring issues associated with the former. … In 2006, its manufacturer AstraZeneca announced that it would not attempt to market ximelagatran after reports of hepatotoxicity (liver damage) during trials, and to discontinue its distribution in countries

    Synonyms: ethyl 2-[[(1R)-1-cyclohexyl-2- [(2S)-2-[[4-(N'-hydroxycarbamimidoyl) phenyl]methylcarbamoyl]azetidin-1-yl]- 2-oxo-ethyl]amino]acetate
  8. Drug

    Solenopsis richteri

    go.drugbank.com/drugs/DB11026
    Approved

    When stung, the bites are characterized by sterile pustules that are surrounded by reddened swelling along with redness extending beyond.

    Categories: Non-Standardized Insect Venom Allergenic Extract
  9. Drug

    Evinacumab

    go.drugbank.com/drugs/DB15354
    ApprovedInvestigational

    [L31838] In September and December 2023, evinacumab was also approved by Health Canada and EMA, respectively, for the same indication.[L49956,L49966] … evinacumab became the first-and-only inhibitor of ANGPTL3 to receive FDA approval after it was granted approval for the adjunctive treatment of homozygous familial hypercholesterolemia (HoFH) under the brand name

  10. Drug

    Brepocitinib

    go.drugbank.com/drugs/DB15003
    ApprovedInvestigational

    [L64097] Brepocitinib is not recommended in combination with other JAK inhibitors, other TYK2 inhibitors, or biologic DMARDs.